
GSK expands food allergy pipeline with RAPT purchase
GSK has entered a definitive agreement to acquire RAPT Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for inflammatory and immunologic diseases. The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody, currently in Phase IIb clinical development for prophylactic protection against food allergens. Under the terms of the… Read More

